World Retirement Companions LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 3.7% within the third quarter, in keeping with the corporate in its most up-to-date 13F submitting with the Securities and Alternate Fee (SEC). The agency owned 15,945 shares of the corporate’s inventory after buying a further 575 shares through the interval. World Retirement Companions LLC’s holdings in AstraZeneca had been value $1,242,000 as of its most up-to-date submitting with the Securities and Alternate Fee (SEC).
Different massive buyers additionally just lately modified their holdings of the corporate. GHP Funding Advisors Inc. bought a brand new place in shares of AstraZeneca through the 2nd quarter valued at $26,000. Pathway Monetary Advisers LLC bought a brand new place in shares of AstraZeneca through the 1st quarter valued at $29,000. Hobbs Group Advisors LLC bought a brand new place in shares of AstraZeneca through the 2nd quarter valued at $35,000. Versant Capital Administration Inc lifted its stake in shares of AstraZeneca by 1,614.8% through the 2nd quarter. Versant Capital Administration Inc now owns 463 shares of the corporate’s inventory valued at $36,000 after shopping for a further 436 shares within the final quarter. Lastly, RFP Monetary Group LLC lifted its stake in AstraZeneca by 56.3% within the 1st quarter. RFP Monetary Group LLC now owns 494 shares of the corporate’s inventory value $33,000 after buying a further 178 shares within the final quarter. Hedge funds and different institutional buyers personal 20.35% of the corporate’s inventory.
Analyst Upgrades and Downgrades
A number of brokerages have commented on AZN. Barclays upgraded shares of AstraZeneca to a “strong-buy” score in a analysis notice on Monday, June twenty fourth. Erste Group Financial institution upgraded shares of AstraZeneca from a “maintain” score to a “purchase” score in a analysis notice on Wednesday, September eleventh. TD Cowen boosted their worth goal on shares of AstraZeneca from $90.00 to $95.00 and gave the inventory a “purchase” score in a analysis notice on Monday, August twelfth. Deutsche Financial institution Aktiengesellschaft reduce shares of AstraZeneca from a “maintain” score to a “promote” score in a analysis notice on Friday, September thirteenth. Lastly, Citigroup upgraded shares of AstraZeneca to a “strong-buy” score in a analysis notice on Monday, June twenty fourth. One equities analysis analyst has rated the inventory with a promote score, one has issued a maintain score, seven have given a purchase score and two have assigned a powerful purchase score to the corporate. In accordance with MarketBeat.com, the corporate presently has a consensus score of “Reasonable Purchase” and a consensus worth goal of $89.75.
Learn Our Newest Inventory Evaluation on AZN
AstraZeneca Inventory Up 0.3 %
Shares of NASDAQ AZN opened at $78.26 on Friday. The agency’s 50-day shifting common worth is $81.13 and its 200-day shifting common worth is $78.20. The corporate has a present ratio of 0.89, a fast ratio of 0.69 and a debt-to-equity ratio of 0.69. The inventory has a market capitalization of $242.65 billion, a price-to-earnings ratio of 38.36, a P/E/G ratio of 1.44 and a beta of 0.46. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month excessive of $87.68.
AstraZeneca (NASDAQ:AZN – Get Free Report) final issued its quarterly earnings outcomes on Thursday, July twenty fifth. The corporate reported $0.99 EPS for the quarter, beating the consensus estimate of $0.98 by $0.01. The corporate had income of $12.45 billion for the quarter, in comparison with the consensus estimate of $12.62 billion. AstraZeneca had a internet margin of 13.11% and a return on fairness of 29.34%. The agency’s income was up 9.1% in comparison with the identical quarter final 12 months. Throughout the identical interval within the prior 12 months, the agency posted $1.08 EPS. On common, equities analysis analysts anticipate that AstraZeneca PLC will put up 4.07 EPS for the present fiscal 12 months.
AstraZeneca Cuts Dividend
The corporate additionally just lately declared a Semi-Annual dividend, which was paid on Monday, September ninth. Traders of document on Friday, August ninth had been issued a dividend of $0.49 per share. The ex-dividend date was Friday, August ninth. This represents a yield of 1.8%. AstraZeneca’s payout ratio is 48.04%.
AstraZeneca Firm Profile
AstraZeneca PLC, a biopharmaceutical firm, focuses on the invention, growth, manufacture, and commercialization of prescription medicines. The corporate’s marketed merchandise embody Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
Wish to see what different hedge funds are holding AZN? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Free Report).
Obtain Information & Rankings for AstraZeneca Day by day – Enter your electronic mail deal with under to obtain a concise every day abstract of the newest information and analysts’ scores for AstraZeneca and associated firms with MarketBeat.com’s FREE every day electronic mail e-newsletter.
